MET (c-Met) protein overexpression is an emerging protein biomarker in non-small cell lung cancer
Unlocking new therapeutic avenues and optimizing diagnostic strategies for NSCLC
This analysis synthesizes key findings on MET protein overexpression (OE) as a crucial, actionable biomarker in non-small cell lung cancer (NSCLC). We delve into its prevalence, prognostic value, and the complexities of IHC-based testing, including heterogeneity and stability. Discover how this emerging biomarker, targetable by antibody-drug conjugates (ADCs), can inform treatment decisions and refine diagnostic protocols in real-world clinical settings.
Executive Impact: Key Metrics for Oncology Innovation
Leveraging MET protein OE as a biomarker presents significant opportunities for enhanced patient outcomes and diagnostic precision in NSCLC.
0
MET OE Prevalence
0
Treatment Response Rate (ADCs)
0
IHC Reproducibility Improvement
Deep Analysis & Enterprise Applications
Select a topic to dive deeper, then explore the specific findings from the research, rebuilt as interactive, enterprise-focused modules.
75%
Max MET Protein OE Prevalence in NSCLC
MET protein overexpression is highly prevalent in NSCLC, with reported rates varying between 15% and 75% depending on methodologies. This significant prevalence indicates a large patient population that could benefit from MET-targeted therapies like ADCs.
| Feature | MET Protein OE | MET Exon 14 Skipping | MET Amplification |
|---|---|---|---|
| Prevalence in NSCLC | 15-75% | 3-4% | 2-5% |
| Detection Method | IHC | NGS, RT-PCR | FISH, NGS |
| Actionability | Emerging (ADCs) | Established (TKIs) | Established (TKIs) |
| Prognostic Value | Variable (some studies show poor prognosis) | Poor clinical outcomes | Poor clinical outcomes |
2.18
Hazard Ratio for Worse OS with High MET OE
High MET protein overexpression has been associated with worse overall survival in some meta-analyses, indicating its potential as a negative prognostic biomarker in NSCLC. This highlights the importance of early detection and targeted intervention.
Enterprise Process Flow
Tissue Sample Collection & Processing
→
Fixation Duration & Methods
→
Antibody Clone Selection
→
Antigen Retrieval & Staining
→
Interpretation & Quantification
→
Inter-Observer Variation Mitigation
48%
Reduction in MET IHC Interobserver Variation with Training
Standardization and training significantly improve the reproducibility of MET IHC scoring. The LCMC 2.0 pathologist group demonstrated a 48% improvement in interobserver concordance after an interactive training program, underscoring the need for validated protocols.
LUMINOSITY Trial: Teliso-V for High MET OE NSCLC
Problem: Limited targeted therapies for EGFR-wildtype non-squamous NSCLC with MET protein OE.
Solution: The phase II LUMINOSITY trial evaluated Telisotuzumab Vedotin (Teliso-V), a MET-targeted ADC, in patients with MET protein-overexpressing EGFR-wildtype non-squamous NSCLC.
Outcome: Patients with high MET protein OE (≥50% tumor cells with 3+ staining) showed durable responses with an Overall Response Rate (ORR) of 35%. This led to accelerated FDA approval, highlighting Teliso-V's clinical actionability and the value of MET protein OE as a predictive biomarker.
Key Metrics:
- ORR: 35% (high MET OE)
- Accelerated FDA Approval: Yes
Advanced ROI Calculator
Understand the potential financial and efficiency gains by integrating advanced MET protein OE diagnostics and ADC-based therapeutics into your oncology practice. Optimize patient selection and treatment outcomes.
Annual Cost Savings
$0
Hours Reclaimed Annually
0
Your Implementation Roadmap
A phased approach to integrate MET protein OE diagnostics and targeted therapies effectively into your clinical practice.
Phase 1: Diagnostic Assay Validation
Establish and validate an FDA-approved IHC assay for MET protein OE within your pathology lab, ensuring reproducibility and accuracy across all technicians and equipment.
Phase 2: Multidisciplinary Team Integration
Form a dedicated MET tumor board, including pathologists, oncologists, and oncology nurses, to develop standardized protocols for patient selection and treatment sequencing.
Phase 3: Clinical Pathway Implementation
Integrate MET protein OE testing into routine NSCLC diagnostic workflows, enabling timely patient identification for MET-targeted ADC therapies like Telisotuzumab Vedotin.
Phase 4: Ongoing Monitoring & Optimization
Implement a system for continuous monitoring of treatment responses and adverse events, gathering real-world evidence to refine patient management strategies and improve outcomes.
Ready to Transform Your Oncology Practice?
Connect with our experts to design a tailored strategy for integrating MET protein OE biomarker testing and targeted ADC therapies.
Ready to Get Started?
Book Your Free Consultation.
Let's Discuss Your AI Strategy!
Lets Discuss Your Needs
Select a Date
Sun
Mon
Tue
Wed
Thu
Fri
Sat